Trial reportThe Journal of clinical endocrinology and metabolism2026
Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults.
Trial report in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of sarcopenia and muscle attenuation with clinical outcomes in patients with diabetic foot: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Sarcopenia in breast cancer: prognostic values and emerging therapeutic strategies.Frontiers in surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
contextGLP-1 receptor agonists have revolutionized the treatment of obesity and type 2 diabetes, but may cause excess muscle loss. Inhibitors of the myostatin-activin pathway can cause fat loss and skeletal muscle gain, but the effect of chronic pathway inhibition on human cardiac muscle is not known.
objectiveInvestigate the effects of extended inhibition of the myostatin-activin pathway on cardiovascular parameters in healthy older adults.
designRandomized, double-blind, placebo-controlled study with 6 months of treatment and up to 6 months of follow-up.
settingSingle commercial study site.
participants68 healthy community-living men and women aged 60 to 86 years.
interventionsIntravenous bimagrumab 10 mg/kg or placebo.
main outcome measuresCardiac magnetic resonance assessment of changes in left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF). Changes in total lean body mass (LBM) and total body fat mass (FM) by dual energy X-ray absorptiometry (DXA).
resultsAt 6 months, no clinically relevant change was observed in LVMI (least squares mean [90% confidence interval] 1.6 g/m2 [-0.2, 3.4], P = .148) or LVEF (2.0% [-0.4, 4.4], P = .176) between treatments. Total LBM (mean [standard deviation]) increased by 5.5% [3.6], and FM decreased by -14% [8.9] with bimagrumab vs placebo (both P < .001).
conclusionSix months of myostatin-activin pathway inhibition with bimagrumab had no effect on cardiac structure or function in healthy older adults compared to placebo. These results support consideration of bimagrumab as a skeletal muscle-sparing intervention in adults undergoing weight loss with GLP-1 receptor agonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.